Rhythm Pharmaceuticals Inc RYTM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $51.77
- Day Range
- $49.11–51.57
- 52-Week Range
- $20.97–55.64
- Bid/Ask
- $51.01 / $51.07
- Market Cap
- $3.12 Bil
- Volume/Avg
- 327,395 / 436,810
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 29.85
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 226
- Website
- http://www.rhythmtx.com
Comparables
Valuation
|
Metric
|
RYTM
|
UTHR
|
DYN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 15.00 | — |
Price/Book Value | 79.21 | 2.75 | 4.59 |
Price/Sales | 29.85 | 6.63 | — |
Price/Cash Flow | — | 14.21 | — |
Price/Earnings
RYTM
UTHR
DYN
Financial Strength
|
Metric
|
RYTM
|
UTHR
|
DYN
|
|---|---|---|---|
Quick Ratio | 6.15 | 3.92 | 26.18 |
Current Ratio | 6.53 | 4.35 | 26.63 |
Interest Coverage | −14.98 | 22.67 | — |
Quick Ratio
RYTM
UTHR
DYN
Profitability
|
Metric
|
RYTM
|
UTHR
|
DYN
|
|---|---|---|---|
Return on Assets (Normalized) | −73.06% | 16.95% | −55.93% |
Return on Equity (Normalized) | −183.91% | 20.53% | −64.68% |
Return on Invested Capital (Normalized) | −148.21% | 16.62% | −63.67% |
Return on Assets
RYTM
UTHR
DYN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Xlnfhrfjpm | Zknh | $518.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Yhpyrqnm | Sbqfwr | $119.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Lvpscpfk | Wdbnkr | $114.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Wdsyghjps | Twtslg | $34.9 Bil | |||
| argenx SE ADR
ARGX
| Xvhqtcft | Pvcz | $32.9 Bil | |||
| BioNTech SE ADR
BNTX
| Wqylnkhq | Lclx | $28.3 Bil | |||
| Moderna Inc
MRNA
| Vsflgfxg | Dmxtj | $24.3 Bil | |||
| United Therapeutics Corp
UTHR
| Qjpyflksp | Yrj | $15.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Mlsrpqvnd | Qftdsg | $13.3 Bil | |||
| Incyte Corp
INCY
| Vsptlydw | Bjpbz | $13.0 Bil |
United States